Aura CL

Smarter Fluorescence Cell Imaging

Powered by innovative technology, Aura CL is the ultimate tool to identify, count, and characterize subvisible particle contaminants introduced in cell therapy manufacturing. Get high-throughput insights earlier in discovery to develop cell therapies faster, smarter, and safer.


CAR T Cell Characterization


Product Purity


Automated Dynabeads Analysis



Why Choose Aura CL?

Measuring particles in cell therapy manufacturing has long been a challenge, and the fact that the drug product itself is a particle makes it even harder.

Unlike traditional methods that can't tell cells apart from protein aggregates or harm-causing particles, Aura CL is the first system that can identify them quickly while providing all required cytometric capabilities—counting cells, identifying types, and measuring viability in one simple assay.

Detect and count residual Dynabeads. Finding and counting Dynabeads™️ is easier than ever with Aura CL. Unlike traditional methods that can be subjective, cumbersome, inaccurate and prone to error, this fully automated powerful tool allows you to make an accurate count at high speed.

Analyze small volumes. You only need 5 µL of sample, which allows for CAR-T characterization earlier in cell therapy development.

*Dynabeads refers to the magnetic beads produced by Thermo Fisher Scientific, Inc. Halo Labs is not affiliated with Thermo Fisher Scientific, Inc., and references to Dynabeads or any other third-party trademark do not imply sponsorship, endorsement, or approval.

The First and Only Solution to Detect and Count Dynabeads

Residual Dynabeads in a final product can compromise potency, making bead analysis necessary to meet high quality standards. However, using manual hemocytometry to detect residual Dynabeads has been unreliable because it’s hard to tell the difference between beads and cells.

That's where Aura CL saves the day—this rapid, accurate detection system performed by Side Illumination Membrane Imaging (SIMI) is the only automated product on the market that eliminates human errors for specific and sensitive residual Dynabeads detection that meets the highest quality standards of cell therapy lot release assays.

Take the Guesswork Out of Particle ID

High-throughput and definitive identification of viable cells is critical in cell therapy manufacturing. However, obtaining this key product-purity parameter has been a challenge as classic methods are user intensive and complicated—until now.

Aura CL system takes the guesswork out of cell viability assessments. Forget about using unreliable techniques like morphology and spectroscopy, as well as complicated machine learning libraries, to determine the composition of your sample.

Labeling the particles or groups of interest with fluorescent dyes or antibodies makes it possible to tell the difference between cell and non-cell parts and protein and non-protein parts in complex samples.

Key Specifications

Imaging Area 24.6 mm2
Optics 4x and 10 objectives
Minimum volume 5 μL (assay dependent)
Resolution 1.0 pixel/μm
Detectable size range Range from >1 μm (ECD) to <5 mm (ECD)
BMI read time 1 minute/sample
FMM read time 30 seconds/sample
Software Particle VUE 4.x all-in-one software suite (image capture and analysis)

Useful Documents

  • Sprite

    Specification Sheet

Related Documents

  • Sprite

    Aura Family Brochure

  • Sprite

    Cell Viability Meets Product Purity Webinar

  • Sprite

    Evaluate Cell Therapy Product Purity With Aura CL App note

  • Sprite

    Identify, And Characterize Cellular Versus Non-Cellular Aggregates With The Aura CL App Note

Dynabeads® is registered trademarks of Thermo Fisher Scientific in the United States and/or other countries. All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

Ready to bring fast, decisive, low volume particle characterization to all of your cell therapy development and manufacturing workflows? Get in touch to request a quote.

Frequently Asked Questions

CAR T-cell therapy, a type of immunotherapy, involves genetically modifying a patient's own T cells to recognize and attack cancer cells. The criteria for CAR T-cell therapy eligibility typically include factors such as the type and stage of cancer, previous treatments received, overall health status, and specific genetic markers. Patients must undergo thorough evaluation and screening to determine their suitability for CAR T-cell therapy.


Particle Vue Software

Get particle analysis answers in just a few clicks with flexible, easy-to-use Particle Vue Software.